About: Acquired resistance to osimertinib plus savolitinib is mediated by MET-D1228 and Y1230 mutations in EGFR mutated MET amplified lung cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acquired resistance to osimertinib plus savolitinib is mediated by MET-D1228 and Y1230 mutations in EGFR mutated MET amplified lung cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Acquired resistance to osimertinib plus savolitinib is mediated by MET-D1228 and Y1230 mutations in EGFR mutated MET amplified lung cancer
Creator	Costa, Daniel Rangachari, Deepa Halbert, Brian Kobayashi, Susumu Piper-Vallillo, Andrew
source	PMC
abstract	covid:af348d9a14c33a4f830ce1958240f48e515a6760#abstract
has issue date	2020-06-20(xsd:dateTime)
bibo:doi	10.1016/j.jtocrr.2020.100071
has license	no-cc
sha1sum (hex)	af348d9a14c33a4f830ce1958240f48e515a6760
schema:url	https://doi.org/10.1016/j.jtocrr.2020.100071
resource representing a document's title	Acquired resistance to osimertinib plus savolitinib is mediated by MET-D1228 and Y1230 mutations in EGFR mutated MET amplified lung cancer
has PubMed Central identifier	PMC7305494
resource representing a document's body	covid:af348d9a14c33a4f830ce1958240f48e515a6760#body_text
is schema:about of	named entity 'granted' named entity 'COVID-19' named entity 'resource centre' named entity 'lung cancer' named entity 'Acquired resistance' named entity 'osimertinib' named entity 'fatigue' named entity 'proto-oncogene' named entity 'adjuvant' named entity 'allele frequency' named entity 'toxicity' named entity 'EGFR' named entity 'case report' named entity 'gastrointestinal' named entity 'EGFR' named entity 'cabozantinib' named entity 'savolitinib' named entity 'lung cancer' named entity 'clinical trial' named entity 'MET inhibitor' named entity 'EGFR' named entity 'activation loop' named entity 'mutation' named entity 'case report' named entity 'T790M' named entity 'institutional review board' named entity 'osimertinib' named entity 'acquired resistance' named entity 'chemotherapy' named entity 'cabozantinib' named entity 'type II' named entity 'liquid biopsy' named entity 'LabCorp' named entity 'Integrated Genetics' named entity 'crizotinib' named entity 'exon' named entity 'tumor' named entity 'tepotinib' named entity 'osimertinib' named entity 'radiographic' named entity 'savolitinib' named entity 'preclinical' named entity 'lung cancer' named entity 'savolitinib' named entity 'savolitinib' named entity 'Foundation Medicine' named entity 'type IB' named entity 'Tissue biopsy' named entity 'pack-year' named entity 'EGFR' named entity 'lung adenocarcinoma' named entity 'osimertinib' named entity 'metastatic' named entity 'EGFR' named entity 'EGFR' named entity 'savolitinib' named entity 'metastatic' named entity 'case report' named entity 'savolitinib' named entity 'lobectomy' named entity 'receptor tyrosine kinase' named entity 'savolitinib' named entity 'heterogeneity' named entity 'osimertinib' named entity 'MET kinase' named entity 'assay' named entity 'osimertinib' named entity 'EGFR' named entity 'mutation' named entity 'osimertinib' named entity 'MET kinase' named entity 'MET kinase' named entity 'adenocarcinoma' named entity 'EGFR' named entity 'lung adenocarcinoma' named entity 'tyrosine kinase inhibitors' named entity 'tumors' named entity 'savolitinib' named entity 'lung adenocarcinoma' named entity 'Cabozantinib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software